A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine

(2014) Eliezer M Van Allen et al.   NATURE MEDICINE

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

(2014) Filip Janku et al.   Cell Reports

Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen

(2013) Diana E. Ramirez-Ardila et al.   BREAST CANCER RESEARCH AND TREATMENT

BRAFmutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel

(2013) D. Gonzalez et al.   BRITISH JOURNAL OF DERMATOLOGY

A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes

(2013) J.M. Eggington et al.   CLINICAL GENETICS

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

(2013)   GENETICS IN MEDICINE

Incidental findings in clinical genomics: a clarification

(2013)   GENETICS IN MEDICINE

The EGAPP initiative: lessons learned

(2013)   GENETICS IN MEDICINE

ACMG clinical laboratory standards for next-generation sequencing

(2013) Heidi L. Rehm et al.   GENETICS IN MEDICINE

Comparison and validation of genomic predictors for anticancer drug sensitivity

(2013) Simon Papillon-Cavanagh et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

(2013) Neal I. Lindeman et al.   Journal of Thoracic Oncology

A guide to GRADE guidelines for the readers of JTH

(2013) G. Guyatt et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma

(2012) A. Thomas et al.   ANNALS OF ONCOLOGY

PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

(2012) F. Janku et al.   CANCER RESEARCH

GRADE guidelines—an introduction to the 10th–13th articles in the series

(2012) Gordon H. Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles—continuous outcomes

(2012) Gordon H. Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Raise standards for preclinical cancer research

(2012) C. Glenn Begley et al.   NATURE

Assuring the quality of next-generation sequencing in clinical laboratory practice

(2012) Amy S Gargis et al.   NATURE BIOTECHNOLOGY

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human Exomes

(2012) J. A. Tennessen et al.   SCIENCE

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Consensus: a framework for evaluation of uncertain gene variants in laboratory test reporting

(2012) David K Crockett et al.   Genome Medicine

GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables

(2011) Gordon Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)

(2011) Gordon H. Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Implementation of Comprehensive Strategies to Characterize Cancer Genomes: Opportunities and Challenges

(2011) L. E. MacConaill et al.   Cancer Discovery

GRADE guidelines: 2. Framing the question and deciding on important outcomes

(2010) Gordon H. Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology

(2010) Gordon H. Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer

(2008) N Nakayama et al.   BRITISH JOURNAL OF CANCER

ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007

(2008) C Sue Richards et al.   GENETICS IN MEDICINE

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results

(2008) Sharon E. Plon et al.   HUMAN MUTATION